Literature DB >> 2466406

Monoclonal antibody to a human pancreatic carcinoma cell line recognizes gastrointestinal neoplasms.

H J Kahn1, H Yeger, R Loftus, M H Goldrosen.   

Abstract

A monoclonal antibody designated RWP1.1 was produced against a human pancreatic carcinoma cell line RWP1. This antibody was shown to recognize an epitope of carcinoembryonic antigen. The reactivity of the antibody was evaluated on formalin-fixed normal tissues, 86 malignant neoplasms, 10 colonic polyps, and 6 cases of chronic pancreatitis using the peroxidase anti-peroxidase technique. RWP1.1 did not react with normal tissues apart from weak staining of fetal pancreatic ducts. This antibody preferentially reacted with primary and metastatic adenocarcinomas of the colon, stomach, pancreas, and colonic polyps but not with most adenocarcinomas from other sites nor with other types of tumors or cases of chronic pancreatitis. It also reacted with colon adenocarcinomas on frozen sections. The restricted specificity of this antibody could be used in differentiating gastrointestinal adenocarcinomas from other types of tumors including adenocarcinomas from other sites and most pancreatic adenocarcinomas from chronic pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466406      PMCID: PMC1879514     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas.

Authors:  M Lieber; J Mazzetta; W Nelson-Rees; M Kaplan; G Todaro
Journal:  Int J Cancer       Date:  1975-05-15       Impact factor: 7.396

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Purification and characterization of carcinoembryonic antigen-related antigens in normal adult feces.

Authors:  M Kuroki; Y Koga; Y Matsuoka
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

4.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

5.  Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase.

Authors:  A A Yunis; G K Arimura; D J Russin
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

6.  Proteolytic release of antigenic fragments corresponding to normal fecal antigen and non-specific cross-reacting antigen from carcinoembryonic antigen.

Authors:  Y Matsuoka; Y Koga; H Maruta; M Yoshino; E Tsuru
Journal:  Int J Cancer       Date:  1978-05-15       Impact factor: 7.396

7.  Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma.

Authors:  M Kaku; T Nishiyama; K Yagawa; M Abe
Journal:  Gan       Date:  1980-10

8.  Reactivity of monoclonal anti-human pancreatic carcinoma antibodies AR2-20 and AR1-28 with tumors of nonpancreatic origin.

Authors:  J Chin; R Zuna; F Miller
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

9.  Establishment and characteristics of a human pancreatic cancer cell line (HCG-25).

Authors:  T Akagi; T Kimoto
Journal:  Acta Pathol Jpn       Date:  1977-01

10.  Establishment and characterization of primary human pancreatic carcinoma in continuous cell culture and in nude mice.

Authors:  A G Grant; D Duke; J Hermon-Taylor
Journal:  Br J Cancer       Date:  1979-02       Impact factor: 7.640

View more
  1 in total

1.  D-14 monoclonal antibody to carcinoembryonic antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human colorectal carcinoma, tumors of non-colorectal origin and normal tissues.

Authors:  Z P Pavelic; N J Petrelli; L Herrera; M M Vaughan; J S Paecock; L Pavelic
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.